Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

761. Cost-effectiveness of the influenza vaccine in a healthy, working-age population

Cost-effectiveness of the influenza vaccine in a healthy, working-age population Cost-effectiveness of the influenza vaccine in a healthy, working-age population Cost-effectiveness of the influenza vaccine in a healthy, working-age population Campbell D S, Rumley M H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination: split virion vaccine composed of A/Texas/36/91 (H1N1), A/Beijing/353/89 (H3N2) and B/Panama/45/90. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Three groups of workers (volunteers who were vaccinated) from three factories, compared to a group of non-vaccinated factory workers from three other factories within a 120 miles

1997 NHS Economic Evaluation Database.

762. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. (Abstract)

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. The current study evaluated whether intranasal administration of the sialic acid analog 4-guanidino-Neu5Ac2en (GG167), an inhibitor of influenza virus neuraminidase, was effective and safe in either preventing or treating experimental human influenza.Four randomized, double-blind, placebo-controlled trials involving three prophylaxis limbs, two early treatment limbs, and one delayed treatment limb were (...) conducted.Isolation in individual rooms.Susceptible (serum hemagglutination-inhibition antibody titer < or = 1:8) adult volunteers (n = 166) were inoculated intranasally with 10(5) TCID50 influenza A/Texas/91 (H1N1) virus.GG167, 3.6 to 16 mg, was administered intranasally two or six times daily beginning 4 hours before inoculation (prophylaxis) or 1 or 2 days afterward (early or delayed treatment).Virological measures were frequency of infection based on viral shedding and/or seroconversion (prophylaxis

1996 JAMA Controlled trial quality: uncertain

763. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. (Abstract)

Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. To evaluate maternal responses to Haemophilus influenzae type b (Hib) polysaccharide-tetanus protein conjugate (polyribosylribitol phosphate-tetanus or PRP-T) given to pregnant Gambian women, the transplacental transfer of antibody, and the effect of maternal immunization on infant responses to the vaccine.An open, randomized immunogenicity study.A busy urban health center

1996 JAMA Controlled trial quality: uncertain

764. Influenza vaccination and older people

Influenza vaccination and older people Influenza vaccination and older people Influenza vaccination and older people NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Influenza vaccination and older people. York: Centre for Reviews and Dissemination (CRD (...) ) 1996: 4 Authors' objectives To summarise the evidence relating to influenza vaccination in older people. Authors' conclusions Most deaths related to influenza occur in people over 65, and those with underlying chronic medical conditions are at particularly high risk. Modern influenza vaccines are effective and free from serious side effects. Research evidence shows that annual influenza vaccination of all older people is a cost effective way of reducing influenza-related deaths and illness. All

1996 Health Technology Assessment (HTA) Database.

765. The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines

The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines Mills O F, Rhoads G G Authors' objectives To assess the efficacy of pneumococcal polysaccharide and Haemophilus (...) influenzae type B polyribosylribitol phosphate (Hib-PRP) vaccines. Searching MEDLINE and the Science Citation Index were searched for English language articles, and the references cited in the retrieved articles were examined. No keywords or other restrictions are stated. Study selection Study designs of evaluations included in the review The review includes RCTs and case-control studies. Inclusion criteria for the RCTs were randomisation, placebo control and a measure of vaccine efficacy. For case

1996 DARE.

766. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France

Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France Livartowski A, Boucher J, Detournay B, Reinert P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccine against Haemophilus influenzae type b (Hib). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population The study population was a hypothetical cohort of the entire generation of French children aged under five years in 1990 (n

1996 NHS Economic Evaluation Database.

767. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. (Abstract)

Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. To evaluate the safety and immunogenicity of two Haemophilus influenzae type b (Hib) conjugate vaccines when administered in serial combination. These vaccines consisted of Hib capsular polysaccharide polyribosyl-ribitol phosphate (PRP) conjugated to the meningococcal outer membrane protein (OMP) complex (PRP-OMP) and H influenzae oligosaccharide conjugated to a mutant toxin (CRM197) isolated from

1995 JAMA Controlled trial quality: uncertain

768. The effectiveness of vaccination against influenza in healthy, working adults. (Abstract)

The effectiveness of vaccination against influenza in healthy, working adults. Although influenza causes substantial morbidity and mortality in all age groups, current recommendations emphasize annual immunization for people at high risk for complications of influenza. We conducted a double-blind, placebo-controlled trial of vaccination against influenza in healthy, working adults.In the fall of 1994, we recruited working adults from 18 to 64 years of age from in and around the Minneapolis-St (...) . Paul area and randomly assigned them to receive either influenza vaccine or placebo injections. The primary study outcomes included upper respiratory illnesses, absenteeism from work because of upper respiratory illnesses, and visits to physicians' offices for upper respiratory illnesses. The economic benefits of vaccination were analyzed by estimating the direct and indirect costs associated with immunization and with upper respiratory illnesses.We enrolled a total of 849 subjects. Baseline

1995 NEJM Controlled trial quality: predicted high

769. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature

The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A Authors' objectives To review the protective efficacy of influenza vaccination in elderly people. Searching MEDLINE was searched (search (...) dates are unclear)using the terms 'influenza vaccine', 'vaccine efficacy', 'elderly', 'mortality', 'hospitalised' and 'pneumonia', and appropriate references in the retrieved literature were identified. Study selection Study designs of evaluations included in the review Eleven retrospective cohort trials, 9 prospective cohort trials, 3 case-control trials and 1 randomised controlled trial (RCT). Only cohort trials were used for the meta-analysis (n=20). Specific interventions included in the review

1995 DARE.

770. Efectividad de la vacunacion antigripal en los ancianos: una revision critica de la bibliografia [Influenza vaccine effectiveness in the elderly: a critical literature review]

of hospitalisation from flu and pneumonia was 0.63 (CI: 0.54, 0.72, p<0.0001). The percentage of hospitalisations prevented by vaccination was 37.4% (CI: 27.81, 45.72). Authors' conclusions The annual vaccination of elderly persons over the age of 65 is effective in the prevention of influenza. CRD commentary A well-structured and conducted review with particularly good use of validity criteria. Since the search is limited to MEDLINE (English and Spanish) it may not be comprehensive. Studies with different (...) Efectividad de la vacunacion antigripal en los ancianos: una revision critica de la bibliografia [Influenza vaccine effectiveness in the elderly: a critical literature review] Efectividad de la vacunacion antigripal en los ancianos: una revision critica de la bibliografia [Influenza vaccine effectiveness in the elderly: a critical literature review] Efectividad de la vacunacion antigripal en los ancianos: una revision critica de la bibliografia [Influenza vaccine effectiveness in the elderly

1995 DARE.

771. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease

The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease Hussey G D, Lasser M L, Reekie W D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination for Haemophilus influenzae type B (HiB) disease. Type of intervention Primary prevention Economic study type Cost-benefit analysis Study population Cohort of children born in 1992 Setting Primary care. The economic study was carried out in Cape Town Province, Republic of South Africa. Dates to which data relate 1992 births to age 100 simulation. 1992 prices were

1995 NHS Economic Evaluation Database.

772. Immunogenicity of new virosome influenza vaccine in elderly people. (Abstract)

Immunogenicity of new virosome influenza vaccine in elderly people. The safety and immunogenicity of a new virosome influenza vaccine was compared to commercial whole-virus vaccine and subunit vaccine in elderly people. The virosome vaccine was made by extracting the haemagglutinin from influenza virus and incorporating it into the membrane of liposomes composed of phosphatidylcholine (PC) and phosphatidylethanolamine (PE). 126 residents of a nursing home, aged 63-102, were randomised

1994 Lancet Controlled trial quality: uncertain

773. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. (Abstract)

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. To determine the efficacy of influenza vaccination in elderly people.Randomized double-blind placebo-controlled trial.Fifteen family practices in the Netherlands during influenza season 1991-1992.A total of 1838 subjects aged 60 years or older, not known as belonging to those high-risk groups in which vaccination was previously given.Purified split-virion vaccine containing (...) A/Singapore/6/86(H1N1), A/Beijing/353/89(H3N2), B/Beijing/1/87, and B/Panama/45/90 (n = 927) or intramuscular placebo containing physiological saline solution (n = 911).Patients presenting with influenzalike illness up to 5 months after vaccination; self-reported influenza in postal questionnaires 10 weeks and 5 months after vaccination; serological influenza (fourfold increase of antibody titer between 3 weeks and 5 months after vaccination).The incidence of serological influenza was 4% in the vaccine

1994 JAMA Controlled trial quality: predicted high

774. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. (Abstract)

Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. To assess the effect of priming with diphtheria and tetanus toxoid vaccine (DT) at 1 month of age on the anticapsular polyribosylribitol phosphate (PRP) antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate (PRP-T) or PRP oligosaccharide-cross-reactive mutant diphtheria toxin conjugate (HbOC).Randomized controlled

1994 JAMA Controlled trial quality: uncertain

775. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies

Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus (...) influenzae: a meta-analysis of 12 clinical studies Cooper B C, Mullins P R, Jones M R, Lang S D Authors' objectives To: (1) establish the clinical and bacteriological efficacy of roxithromycin against adult respiratory tract infections caused by Haemophilus influenzae on a per protocol and intention to treat basis; (2) compare the clinical efficacy of once and twice daily regimens of roxithromycin; (3) compare the efficacy of roxithromycin with standard antibiotics; (4) assess the correlation between

1994 DARE.

776. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP

The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) favourably with other medical interventions. CRD Commentary The cost analysis could be clearer. Moreover, no satisfactory explanation was provided for the calculation of QALYs. Source of funding Merck Sharp and Dohme(Australia) Pty Ltd. Bibliographic details Harris A, Hendrie D, Bower C, Payne J, de Klerk N, Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Medical Journal of Australia 1994; 160: 483-488 PubMedID Indexing Status

1994 NHS Economic Evaluation Database.

777. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization Mullooly J P, Bennett M D, Hornbrook M C, Barker W H, Williams W W, Patriarca P A, Rhodes P H Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination against influenza. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Elderly males and females (aged 65+). High risk participants werethose who had medical care contacts for chronic pulmonary

1994 NHS Economic Evaluation Database.

778. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community Full Text available with Trip Pro

The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community Nichol K L, Margolis K L, Wuorenma R N, Von Sternberg T Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccination against influenza Type of intervention Primary prevention Economic study type Cost-effectiveness analysis Study population All persons aged 65 or over, enrolled in a Health Maintenance Organisation (HMO). Setting The practice setting was primary care. The economic study

1994 NHS Economic Evaluation Database.

779. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB)

Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Cost-benefit analysis of general vaccination against Haemophilus influenzae type b (HIB) Trollfors B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Vaccine against Haemophilus influenzae type b (HIB) Type of intervention Primary prevention Economic study type Cost-benefit analysis Study population Children aged 0-14 years. Setting Primary care. The economic study was carried out in Sweden. Dates to which data relate Information on effectiveness related to 1981-83. Dates for resource data were not clearly specified. Price data was not given

1994 NHS Economic Evaluation Database.

780. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. Full Text available with Trip Pro

Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. To assess the frequency and type of side effects after influenza vaccination in elderly people.Randomised double blind placebo controlled study.15 general practices in the southern Netherlands.1806 patients aged 60 or older, of whom 904 received influenza vaccine and 902 placebo.Adverse reactions reported on postal questionnaire completed four weeks after vaccination.210 (23%) patients

1993 BMJ Controlled trial quality: predicted high